Cabaletta Bio (CABA) vs C4 Therapeutics (CCCC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
C4 Therapeutics (CCCC) has outperformed Cabaletta Bio (CABA) over the past year, gaining 24.8% versus a loss of 15.1%. Over five years, CABA leads with a -83.9% price change compared with -93.6% for CCCC. C4 Therapeutics is the larger company by market cap ($346.9 million vs $334.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CABA | CCCC |
|---|---|---|
| Share price | $1.97 | $2.82 |
| Market cap | $334.00M | $346.93M |
| 1-day change | -2.48% | -2.08% |
| YTD return | -10.05% | +47.64% |
| 1-year return | -15.09% | +24.78% |
| 5-year return | -83.93% | -93.57% |
| EPS (TTM) | $-1.51 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.23 | $5.17 |
| 52-week low | $1.83 | $1.69 |
| Distance from 52-week high | -53.43% | -45.45% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +572.59% | +372.70% |
| Average volume | 4.71M | 2.39M |
| Shares outstanding | 169.55M | 123.03M |
| Employees | 154 | 104 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CCCC has outperformed CABA by 39.9 percentage points over the past year.
About Cabaletta Bio
CABA stock →Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Healthcare · Biotechnology · 154 employees
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Healthcare · Biotechnology · 104 employees
CABA vs CCCC FAQ
Which is bigger, Cabaletta Bio or C4 Therapeutics?
C4 Therapeutics (CCCC) is larger, with a market capitalization of $346.93M compared with $334.00M for Cabaletta Bio (CABA).
Which stock has performed better over the past year, CABA or CCCC?
CCCC returned +24.78% over the past 12 months, compared with -15.09% for CABA (price return, excluding dividends). Past performance does not predict future results.
Are Cabaletta Bio and C4 Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.